A new study shows that AI can be used to evaluate the build-up of calcium deposits in the breast arteries from X-ray mammography scans that are used in routine breast cancer screening.

Scientists have discovered a new solution to target cancer causing proteins. They have developed protein like polymers which are capable of grabbing proteins and directing them to the cell’s waste-disposal system.

Researchers have developed a new laboratory model to study rare tumors—BAP1-deficient melanomas—that are resistant to immunotherapies. The model has the potential to transform how therapies are developed for aggressive melanomas that currently have almost no effective treatment options.

Decades of basic research on the foodborne pathogen Listeria monocytogenes have culminated in an unexpected medical application: a novel cancer therapy designed to activate the body’s innate immune system.

A new Seattle-based research accelerator aims to combine artificial intelligence with large-scale biological experiments. AI Bio-Design will develop openly available models, datasets and tools that could support applications ranging from new medicines and plastic-degrading enzymes to energy-efficient biological computers.

Helping smokers quit remains one of the biggest opportunities to reduce tobacco-related disease. New recommendations urge healthcare professionals to include nicotine e-cigarettes among the evidence-based cessation options discussed with adult patients, while acknowledging that long-term safety data remain limited.

Researchers have developed a new AI tool which is capable of successfully measuring the colonoscopy quality by reviewing the footage of the procedure and providing feedback to clinicians to improve care.

GSK has plans to takeover Nuvalent, a Boston-based clinical-stage biopharmaceutical company for 10.6 billion dollars. The biopharmaceutical firm is focused on creating precisely targeted oncology therapies.

Most of our brain’s 100 billion neurons are created before we’re born, but the trickle of neurons created in the adult brain hippocampus could be instrumental in preventing depression, suggest findings from a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons.

Despite substantial investment in pharmaceutical R&D, clinical success rates remain low. As it stands, 90 % of drug candidates entering human trials fail due to unforeseen toxicity or limited efficacy in humans. A key contributor to this attrition is the limited predictive power of traditional preclinical models, particularly 2D cell cultures and animal studies, which often fall short in recapitulating the complexity of human biology. This gap is particularly evident in oncology and organ-specific toxicity assessments, where cellular context and microenvironmental interactions play a critical role in drug response.